pattern which is predominantly nodal, mostly below the aortic bifurcation. Therefore, many of these patients are amenable for local salvage or metastasis-directed therapy. In contrast patients who develop BCR following RPþADT or RPþRTþADT more often have local, skeletal and extrapelvic nodal relapse and are therefore less likely to benefit from local salvage or metastasis-directed therapy. INTRODUCTION AND OBJECTIVES: Simultaneous 68Ga-PSMA-11 PET/MRI showed some improvement in the detection of recurrent prostate cancer at low serum prostate specific antigen (PSA) levels between 0.2 -0.5 ng/ml compared to the already high detection rate of 68Ga-PSMA-11 PET/CT. Our group therefore analyzed all patients with early biochemical recurrence (EBR) and PSA values 0.5 ng/ml to assess the detection rate for 68Ga-PSMA-11 PET/MRI and its effect on salvage radiotherapy.
INTRODUCTION AND OBJECTIVES: Simultaneous 68Ga-PSMA-11 PET/MRI showed some improvement in the detection of recurrent prostate cancer at low serum prostate specific antigen (PSA) levels between 0.2 -0.5 ng/ml compared to the already high detection rate of 68Ga-PSMA-11 PET/CT. Our group therefore analyzed all patients with early biochemical recurrence (EBR) and PSA values 0.5 ng/ml to assess the detection rate for 68Ga-PSMA-11 PET/MRI and its effect on salvage radiotherapy. METHODS: We retrospectively analyzed a cohort of 66 consecutive patients who underwent a 68Ga-PSMA-11 PET/MRI for EBR with a PSA value 0.5 ng/ml in our institution. Median PSA level was 0.23 ng/ml (interquartile range: 0.22 ng/ml). Detection of PSMApositive lesions within the prostate fossa, local and distant lymph nodes, bones or visceral organs was recorded. All scans with 68Ga-PSMA-11 PET/MRI positive lesions were assessed by a radiation oncologist, to judge if the radiotherapy plan would be adjusted according to the 68Ga-PSMA-11 PET/MRI results.
RESULTS: Overall, in 36 of 66 patients (54.5%) PSMA-positive lesions were detected; in 26 of 40 (65%) patients with a PSA between 0.2 -0.5 ng/ml and in 10 of 26 (38.5%) patients with a PSA < 0.2 ng/ml. Overall 4 of the 66 patients were scanned with rising PSA levels after previous ADT. In all of those patients, PSMA positive lesions were detected. Even at those low PSA values, only 8 of 66 (12.1%) of patients had local recurrence only. In 23 patients lymph nodes and in 5 patients bone metastases were detected on 68Ga-PSMA-11 PET/ MRI. The radiotherapy plan would have been changed according to the disease distribution in 25 of 66 patients (37.8%).
CONCLUSIONS: Our data confirm that 68Ga-PSMA-11 PET/ MRI has a high detection rate for recurrent prostate cancer, even at low PSA levels 0.5 ng/ml and shows that even at very low PSA values the radiotherapy would have been adapted based on the 68Ga-PSMA-11 PET/MRI results in nearly 40% of the patients. INTRODUCTION AND OBJECTIVES: Despite high specificity, PET/CT scan is limited by relatively low sensitivity at a lesion-based analysis in the context of recurrent prostate cancer (PCa). Moreover, underestimation of tumour burden may be related to the extent of tracer uptake. We hypothesized that under-estimation of tumour burden varies significantly according to PET/CT tracer by PSA level at salvage lymph node dissection (SLND) METHODS: We included 458 patients who received extended SLND at eleven tertiary referral centres. All patients were diagnosed with PET/CT scan using either 11C-choline (n[293; 64%) or 68Ga-PSMA (n [165; 36%). The study outcome was under-estimation of tumour burden calculated: number of positive nodes at SLND -number of positive spots at PET/CT. Multivariable linear regression analysis (MVA) tested the association between under-estimation of tumour burden and PET/CT tracer (11C-choline vs. 68Ga-PSMA). We tested an interaction with PSA and PET/CT tracer for the hypothesis that under-estimation of tumour burden varies significantly by PSA at SLND RESULTS: Median PSA at SLND was 2.0 ng/ml. Number of positive spots at pre-operative PET/CT scan was 1 in 257 (57%), 2 in 104 (23%), and !3 in 93 (20%) patients, respectively. Median number of nodes removed at SLND was 24 (IQR: 15, 35). Number of positive nodes was 0 in 67 (15%), 1 in 104 (23%), 2 in 71 (16%), and !3 in 216 (47%) patients, respectively. Median under-estimation of tumour burden was 1. At MVA, 11C-choline was associated with a higher risk of under-estimation of tumour burden compared to 68Ga-PSMA (linear coefficient: 1.61; p<0.0001). 11C-Choline showed a higher under-estimation at lower PSA levels when compared to 68Ga-PSMA (p<0.0001). However, diagnostic accuracy of the two tracers became similar when PSA level exceeded 3 ng/ml (Figure 1) CONCLUSIONS: 11C-choline under-estimates PCa tumour burden of as compared to 68Ga-PSMA. In particular, the lower the PSA level, the higher the benefit of 68Ga-PSMA. However, the two tracers showed the same diagnostic accuracy in detecting nodal metastases when PSA exceeds 3 ng/ml
